PI3K-delta inhibitor
- Impairs B-cell-receptor survival signaling → treats B-cell malignancies
- Autoimmune-type toxicities: colitis, hepatitis, pneumonitis
Drugs with this mechanism (1)
- Idelalisib — PI3K-delta inhibitor for B-cell malignancies.
Self-check
- Which survival pathway is impaired by PI3K-delta inhibition?
B-cell-receptor signaling. - Which autoimmune-type lung toxicity can occur?
Pneumonitis.
All mechanisms · Open PI3K-delta inhibitor in the interactive console ↗